Sharechat Logo

Douglas signs new cancer drug R&D deal with Manchester Uni

Wednesday 1st February 2017

Text too small?

Douglas Pharmaceuticals, the country's biggest drugs developer and manufacturer, has signed a research and licensing deal with the University of Manchester's innovation unit, UMI3, to repurpose an HIV drug to prevent early-stage cervical cancer. 

Auckland-based Douglas Pharmaceuticals will sponsor research at Manchester University to build on work, including a phase one trial in Kenya, that's found a drug commonly used to treat HIV was active against human papilloma virus (HPV), which causes almost all cases of cervical cancer. Douglas Pharmaceuticals would then manufacture the therapy and drive development, clinical trials and global commercialisation, focusing at first on a phase two clinical trial in the UK. 

Chief executive Jeff Douglas told BusinessDesk the company has been working with Manchester University for almost two years, and if clinical trials in American and European centres are successful, then they would partner with a multinational company for an international roll-out that could cost "more than tens of millions of dollars". 

Douglas said the Gardasil HPV vaccine had been successful in reducing cervical cancer where it had been rolled out, primarily in the US and Europe, although it was still a relatively new treatment in developed economies.

"There will be other patients requiring treatment that haven't been protected in poorer countries," he said. 

Douglas Pharmaceuticals is on track to reach annual sales of $200 million in the current financial year, and has previously set a target of $244 million in revenue by 2020. 

Douglas said repurposing existing drugs is "an important addition to our business" and while it's "far more expensive than some other work" the returns are better if it's successful, and it can provide new patent protection. 

The company has just set up a new development business in the US, with a team on board in Pennsylvania, which Douglas said he expects to be operational in three months. 

BusinessDesk.co.nz

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Gold Report 23rd July 2018
MARKET CLOSE: NZ shares down on Trump threats, A2 and Pushpay drop while Kathmandu rises
NZ dollar gains as markets fret about political pressure on the Fed
Tougher NZX disclosure obligations get mixed response in listing rules review
The Warehouse cuts up to 140 jobs in restructure; shares unchanged
Trustpower supports intent of emissions target but calls for careful consideration of impacts
NZ govt to consider imposing mānuka honey export criteria on local market
July 23rd Morning Report
NZ dollar gains as Trump bemoans strong greenback, rising US rates
MARKET CLOSE: NZ shares up, led by Fisher & Paykel Healthcare, Ryman

IRG See IRG research reports